International legal practice Osborne Clarke continues to strengthen its rapidly growing intellectual property disputes team with the appointment of Partner Trevor Crosse, a life sciences sector expert and specialist in complex patent disputes, particularly in relation to inventions in the biotech and pharma fields.
Having previously spent over 12 years at Marks & Clerk Law, Trevor has worked on a variety of high-profile patent cases for leading biotech originator companies, including Genentech, Chugai, AbbVie and Pfizer in patent infringement and revocation actions before the English Patents Courts. He also frequently manages and co-ordinates parallel multi-jurisdictional patent proceedings, and advises clients in relation to issues such as freedom to operate analyses, enforcement strategies, SPC eligibility, and regulatory exclusivities.
Trevor also runs patent disputes in relation to other highly technical inventions involving medical devices and MedTech, electronics, telecoms and mechanical engineering. He advises on non-contentious matters such as IP licensing transactions, patent portfolio reviews and strategy, and IP and invention capture policies.
Trevor will be based in London working alongside Partners Arty Rajendra, Will James, Tim Harris, Rob Guthrie and Richard May.
Arty Rajendra, Partner and Head of IP Disputes in the UK, said: “Osborne Clarke is continuing to expand its well-respected IP Disputes team through organic growth and fantastic lateral hires. Trevor’s addition follows the recent lateral hires of Will James (also from Marks & Clerk Law) and Tim Harris (from Bird & Bird), who, like Trevor, have excellent reputations on the UK patent litigation scene.
“We are already advising on several complex UK and international patent disputes, and with Trevor’s arrival, our increased bench strength enables us to act for the widest range of clients with the most sophisticated requirements, particularly in the life sciences field. Our highly experienced patent litigation team is well placed to advise on business critical patent disputes both here in the UK and abroad, including in the imminent Unified Patents Court.”
Trevor said: “Osborne Clarke provides an ideal platform from which to build on a healthy base of patent litigation matters and non-contentious instructions. The firm’s prowess in the tech sector is also attractive, making it well-placed to win instructions on the next generation of life sciences disputes.
“Life sciences companies are increasingly making use of big data and AI-driven approaches for drug discovery, clinical trial design, and personalised medicine. Future patent disputes are going to require teams with deep expertise spanning the tech and life sciences sectors and Osborne Clarke is really well-equipped to provide this to its clients.”
Osborne Clarke’s IP disputes team act for the world’s leading companies to protect and enforce their innovations and brands. The team has extensive experience across number of sectors, and has advised a number of high-profile life sciences clients on patent matters.
